Our goal is to undertake a diverse portfolio of clinically important research in gynaecological cancer that has the greatest potential to improve patient outcomes.
ANZGOG assists members to develop their research by:
- Clear research priorities defined in the Five Year Strategic Plan.
- Peer discussion and mentoring trough tumour working groups.
- Assistance with study development, connecting investigators to statisticians, translational researchers, QOL and other specialists.
- Funding for study development through the annual Fund for New Research grants
- Study funding for special strategic initiatives and support to apply for government and philanthropic grants.
- Peer review at the Research Advisory Committee to determine acceptance as an ANZGOG study.
ANZGOG studies are conducted collaboratively with the NHMRC Clinical Trials Centre (CTC) and the Centre for Biostatistics and Clinical Trials (BaCT) at Peter MacCallum Cancer Centre as well as funds smaller studies through specialist academic institutions.
Annual General Meeting and Research Development Day
The ANZGOG Annual General Meeting and Research Development Day is typically held in October each year in Sydney.
The Research Development Day brings together ANZGOG researchers from all specialties and continues to be both popular and effective in developing new research ideas.
For more information on either of these member-only events please contact Alison Evans at email@example.com
The ANZGOG 2017 Ovarian Cancer Preceptorship was held 17-18 November in Sydney. It was developed for Fellows, PHD students, Registrars and other early career members. Planning us underway for a 2018 Preceptorship.
The 2017 Ovarian Preceptorship learning objectives were to:
- Learn about best clinical practice in the multi-disciplinary management of early and late stage ovarian cancer
- Understand the importance of biology and pathology of common and rare ovarian tumours
- Understand the options for treatment of recurrent disease and how treatment-decisions are made
- Understand the novel therapeutic agents being developed to treat ovarian cancer and how knowledge of genomics and molecular pathways guides drug development
- Learn about the management of patients with symptoms of the disease and the side-effects of treatments.
For more information please contact Alison Evans at firstname.lastname@example.org